- ASSOCIATE PROFESSOR Psychiatry
- ASSOCIATE PROFESSOR Pediatrics
Child & Adolescent Psychiatry
Neurology, American Board of Psychiatry and Neurology
MD, Sackler School of Medicine
Mount Sinai School of Medicine
Fellowship, Child and Adolescent Psychiatry
Mount Sinai Hospital
Excellence in Teaching Award
AAP Junior Faculty Development Award
AACAP Pilot Research Award
Richard L. Scharf Memorial Award for Teaching Excellence
NIMH Outstanding Resident Award
Teacher of the Year Award
Alpha Omega Alpha (AOA)
Dr. Kolevzon's research interests include the biological causes and effective treatment of autism and related pervasive developmental disorders. He is also committed to medical student and residency training and education and interested in developing innovative educational programs.
Kolevzon A, Smith CJ, Schmeidler J, Buxbaum JD. Familial Symptom Domains in Monozygotic Siblings with Autism.. American Journal of Medical Genetics 2004 August; 129(B): 76-81.
Kolevzon A, Weiser M, Gross R, Lubin G, Knobler HY, Schmeidler J, Silverman JM, Reichenberg A. Season of Birth Effects in Autism Spectrum Disorders: Fact or Fiction? . American Journal of Psychiatry 2006; 163(7): 1288-1290.
Kolevzon A, Mathewson K, Hollander E. Selective Serotonin Reuptake Inhibitors in Autism: A Review of Efficacy and Tolerability.. Journal of Clinical Psychiatry 2006; 67: 407-414.
Kolevzon A, Gross R, Reichenberg A. Pre- and Perinatal Risk Factors of Autism: A Review and Integration of Findings.. Archives of Pediatrics and Adolescent Medicine 2007; 161(4): 326-333.
Parikh M, Kolevzon A, Hollander E. Pharmacology of Aggression in Children and Adolescents with Autism: A Review of Efficacy and Tolerability.. Journal of Child and Adolescent Psychopharmacology 2008 April;.
Kolevzon A, Simeon D. Psychiatry Essentials: A Systematic Review.. Philadelphia, PA, Hanley and Belfus;.
Kolevzon A, Katz CL. Psychiatry History Taking. Laguna Hills, CA, Current Clinical Strategies;.
Kolevzon A, Stewart DG, editors. Psychiatry Pearls. Philadelphia, PA, Hanley and Belfus;.
- A Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Adolescents and Adults with Fragile X
- Phelan-McDermid Syndrome: Insights into Synaptic Pathology and Novel Therapeutics in ASD
- A Randomized, Double-blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Children with Fragile X Syndrome
- Trichuris Suis Ova Treatment of Adult Autism Symptom Domains
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kolevzon did not report having any of the following types of financial relationships with industry during 2012 and/or 2013: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.